Core Viewpoint - Benitec Biopharma Inc. reported its financial results for the third fiscal quarter ended March 31, 2025, highlighting significant increases in expenses and net loss, while also providing updates on its clinical development of BB-301 for Oculopharyngeal Muscular Dystrophy (OPMD) [1][3][4]. Financial Highlights - Total expenses for Q3 2025 were $10.2 million, up from $4.1 million in Q3 2024, marking a 148.8% increase [3]. - Research and development expenses were $6.0 million compared to $2.6 million in the same quarter of the previous year, reflecting a 130.8% increase, primarily due to ongoing clinical development of BB-301 [3]. - General and administrative expenses rose to $4.2 million from $1.6 million year-over-year, an increase of 162.5% [3]. - The loss from operations for Q3 2025 was $10.2 million, compared to a loss of $4.1 million in Q3 2024, indicating a 148.8% increase in operational losses [4]. - Net loss attributable to shareholders for Q3 2025 was $9.4 million, or $0.24 per share, compared to a net loss of $4.3 million, or $0.23 per share, in Q3 2024 [4][7]. - As of March 31, 2025, the company had $103.6 million in cash and cash equivalents, a significant increase from $50.9 million as of June 30, 2024 [4][5]. Clinical Development Updates - The sixth and final subject of Cohort 1 was treated with a low dose of BB-301 in April 2025, with plans to enroll additional subjects at a higher dose later in the year [2]. - BB-301 is designed to treat dysphagia in OPMD patients by promoting co-expression of a functional version of the PABPN1 protein while silencing the expression of the faulty mutant version [8]. Company Overview - Benitec Biopharma Inc. is a clinical-stage biotechnology company focused on developing novel genetic medicines using its proprietary "Silence and Replace" DNA-directed RNA interference platform [9]. - The company aims to address chronic and life-threatening conditions, including OPMD, through innovative therapeutic approaches that combine RNA interference with gene therapy [9].

Core Viewpoint - The article emphasizes the importance of identifying sustainable trends in stock prices for short-term investing, highlighting that while price movements can be profitable, they can also reverse quickly, leading to potential losses [1][2]. Group 1: Stock Performance - Benitec Biopharma Limited (BNTC) has shown a solid price increase of 43.2% over the past 12 weeks, indicating strong investor interest [4]. - The stock has also increased by 22.2% in the last four weeks, suggesting that the upward trend is still intact [5]. - BNTC is currently trading at 83.4% of its 52-week high-low range, indicating a potential breakout [5]. Group 2: Fundamental Strength - BNTC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [6]. - The stock has an Average Broker Recommendation of 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term price performance [7]. Group 3: Investment Strategy - The article suggests using the "Recent Price Strength" screen to identify stocks like BNTC that are on an upward trend supported by strong fundamentals [3][8]. - It also mentions that there are over 45 Zacks Premium Screens available for investors to find winning stock picks based on their personal investing styles [8].

Group 1 - Benitec Biopharma Limited (BNTC) is currently outperforming the Medical sector, gaining approximately 14.1% year-to-date, while the sector has lost an average of 3.5% [4] - The Zacks Consensus Estimate for BNTC's full-year earnings has increased by 57.5% in the past quarter, indicating improved analyst sentiment and a more positive earnings outlook [4] - Benitec Biopharma Limited holds a Zacks Rank of 2 (Buy), suggesting a favorable investment opportunity based on earnings estimates and revisions [3] Group 2 - Benitec Biopharma Limited is part of the Medical - Biomedical and Genetics industry, which consists of 508 companies and currently ranks 84 in the Zacks Industry Rank [6] - The Medical - Biomedical and Genetics industry has experienced an average loss of 3.3% year-to-date, further highlighting BNTC's strong performance relative to its peers [6] - Concentra Group (CON), another Medical stock, has also outperformed the sector with a return of 8.9% year-to-date, and it holds a Zacks Rank of 2 (Buy) [5][7]

Core Viewpoint - Benitec Biopharma Limited (BNTC) shows significant upside potential with a mean price target of $25.71, indicating an 85% increase from the current price of $13.90 [1] Price Targets - The average of seven short-term price targets ranges from a low of $17 to a high of $35, with a standard deviation of $6.70, suggesting variability in analyst estimates [2] - The lowest estimate indicates a 22.3% increase, while the highest suggests a 151.8% upside [2] Analyst Consensus - Strong agreement among analysts regarding BNTC's ability to report better earnings than previously predicted supports the potential for stock upside [4] - The Zacks Consensus Estimate for the current year has increased by 0.7% over the past month, with one estimate rising and no negative revisions [12] Zacks Rank - BNTC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Earnings Estimate Revisions - Analysts' optimism regarding BNTC's earnings prospects, reflected in the upward revisions of EPS estimates, correlates strongly with near-term stock price movements [11]

Benitec Biopharma Limited (BNTC) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Individual investo ...

HAYWARD, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") "Silence and Replace" platform, today announced the pricing of its underwritten offering of 1,443,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and a concurrent registered direct ...

Core Viewpoint - Benitec Biopharma Inc. has announced the pricing of an underwritten offering of 1,443,000 shares and a concurrent registered direct offering of 900,000 shares, aiming to raise approximately $30 million to support its product candidate programs and general corporate purposes [1][2]. Group 1: Offering Details - The underwritten offering includes 1,443,000 shares of common stock priced at $13.00 each, and pre-funded warrants priced at $12.9999, which are immediately exercisable at an exercise price of $0.0001 per share [1]. - The concurrent registered direct offering involves 900,000 shares of common stock with long-term investor Suvretta Capital [1]. - The total gross proceeds from both offerings are expected to be around $30 million before deducting any underwriting discounts and expenses [2]. Group 2: Use of Proceeds - The net proceeds from the offerings will be utilized to further develop the company's product candidate programs, along with working capital and other general corporate purposes [2]. Group 3: Management and Governance - In connection with the registered direct offering, discussions have been held regarding the appointment of David Friedman from Suvretta Capital to the company's board of directors, pending board approval [4]. - The company previously appointed Kishen Mehta, a portfolio manager at Suvretta Capital, to its board on June 26, 2024 [4]. Group 4: Company Overview - Benitec Biopharma Inc. is a clinical-stage biotechnology company based in Hayward, California, focusing on developing novel genetic medicines using its proprietary "Silence and Replace" platform [7]. - The company's technology combines RNA interference with gene therapy to create treatments for chronic and life-threatening conditions, including Oculopharyngeal Muscular Dystrophy (OPMD) [7].

-Durable, Clinically Significant Improvements in Swallowing Function Achieved 12-months Post-Treatment with BB-301 for Subject 1- -Durable, Clinically Significant Improvements in Swallowing Function Achieved 12-months Post-Treatment with BB-301 for Subject 2, with Subject 2 Achieving a Clinically Normal Swallowing Profile Following the Significant Reduction in Total Dysphagic Symptom Burden- -Clinically Significant Improvements in Swallowing Function Achieved 3-months Post-Treatment with BB-301 for Subject ...

Core Insights - Benitec Biopharma Inc. has reported durable and clinically significant improvements in swallowing function for subjects treated with BB-301, a gene therapy for Oculopharyngeal Muscular Dystrophy (OPMD) [1][3][19] - The interim clinical study results will be presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference, highlighting the efficacy of BB-301 in reducing dysphagic symptom burden [1][2] Summary of Clinical Results - Subject 1 showed a 37% reduction in Total Pharyngeal Residue for Thin Liquid, an 18% reduction for Solid Food, and a 29% reduction for Thick Liquids, with a 41% reduction in total dysphagic symptom burden 12 months post-treatment [8][9] - Subject 2 experienced a significant reduction in pathologic sequential swallows, achieving a clinically normal swallowing profile with a 91% reduction in total dysphagic symptom burden, resulting in an SSQ score of 68 units [10][12] - Subject 3 achieved complete resolution of pathologic sequential swallows and a 68% reduction in total dysphagic symptom burden, with an SSQ score of 70 units indicative of a clinically normal swallowing profile at 3 months post-treatment [13][15] Study Design and Methodology - The study is a Phase 1b/2a, open-label, dose escalation trial assessing the safety and clinical activity of BB-301 in OPMD patients [3][19] - Key assessment methods include videofluoroscopic swallowing study (VFSS) for swallowing efficiency and effectiveness, and the Sydney Swallow Questionnaire (SSQ) for patient-reported outcomes [2][5] Company Overview - Benitec Biopharma Inc. is focused on developing novel genetic medicines using its proprietary "Silence and Replace" DNA-directed RNA interference platform, targeting chronic and life-threatening conditions like OPMD [19]

Core Viewpoint - Benitec Biopharma Inc. is actively participating in several upcoming healthcare conferences to showcase its advancements in gene therapy and its proprietary "Silence and Replace" platform [1][2][3]. Group 1: Company Overview - Benitec Biopharma Inc. is a clinical-stage biotechnology company based in Hayward, California, focused on developing novel genetic medicines [4]. - The company utilizes a proprietary "Silence and Replace" DNA-directed RNA interference platform that combines RNA interference with gene therapy [4]. - Benitec is developing therapeutics targeting chronic and life-threatening conditions, including Oculopharyngeal Muscular Dystrophy (OPMD) [4]. Group 2: Upcoming Conferences - Benitec will present at the TD Cowen 45 Annual Health Care Conference on March 5, 2025, from 9:50 AM to 10:20 AM EST, with a format of presentation and 1x1 meetings [2]. - The company will also participate in the Leerink Partners Global Healthcare Conference on March 12, 2025, from 9:20 AM to 9:50 AM EST, featuring a fireside chat and 1x1 meetings [2]. - Additionally, Benitec will be involved in the 2025 Muscular Dystrophy Association Clinical & Scientific Conference, with a panel discussion on March 18, 2025, and a presentation on March 19, 2025 [3].